Skip to main content
Top
Published in: Current Rheumatology Reports 3/2010

01-06-2010

Update on the Assessment of Children with Juvenile Idiopathic Inflammatory Myopathy

Author: Adam M. Huber

Published in: Current Rheumatology Reports | Issue 3/2010

Login to get access

Abstract

The availability of validated measurement tools to assess children with juvenile idiopathic inflammatory myopathies is critical to clinical care and to ongoing research into new therapeutic modalities and approaches. Recent work has led to the development of tools for assessment of muscle strength and physical function, skin disease, global disease activity and damage, extramuscular disease, and quality of life. Ongoing work is attempting to integrate these assessments into core sets and definitions of improvement and flare. Future work will refine these assessments and definitions and—where there are multiple choices—determine which tools constitute an optimal assessment.
Literature
1.
go back to reference Mendez EP, Lipton R, Ramsey-Goldman R, et al.; NIAMS Juvenile DM Registry Physician Referral Group: US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003, 49:300–305.CrossRefPubMed Mendez EP, Lipton R, Ramsey-Goldman R, et al.; NIAMS Juvenile DM Registry Physician Referral Group: US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003, 49:300–305.CrossRefPubMed
2.
go back to reference Medical Research Council: Aids to the Investigation of Peripheral Nerve Injuries. Memorandum No. 7, edn 2. London: Her Majesty’s Stationery Office; 1943. Medical Research Council: Aids to the Investigation of Peripheral Nerve Injuries. Memorandum No. 7, edn 2. London: Her Majesty’s Stationery Office; 1943.
3.
go back to reference Kendall FP, McCreary EK, Provance PG: Muscles: Testing and Function, edn 4. Baltimore, MD: Williams & Wilkins; 1993. Kendall FP, McCreary EK, Provance PG: Muscles: Testing and Function, edn 4. Baltimore, MD: Williams & Wilkins; 1993.
4.
go back to reference Jain M, Smith M, Cintas H, et al.: Intra-rater and inter-rater reliability of the 10-point manual muscle test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr 2006, 26:5–17.PubMed Jain M, Smith M, Cintas H, et al.: Intra-rater and inter-rater reliability of the 10-point manual muscle test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr 2006, 26:5–17.PubMed
5.
go back to reference • Rider LG, Koziol D, Giannini EH, et al.: Validation of manual muscle testing and a subset or eight muscles (MMT8) for adult and juvenile idiopathic inflammatory myopathy. Arthritis Care Res 2010, 62(4):465–472. This important study documents that the MMT8 has measurement characteristics that are similar to the full 26-muscle version. • Rider LG, Koziol D, Giannini EH, et al.: Validation of manual muscle testing and a subset or eight muscles (MMT8) for adult and juvenile idiopathic inflammatory myopathy. Arthritis Care Res 2010, 62(4):465–472. This important study documents that the MMT8 has measurement characteristics that are similar to the full 26-muscle version.
6.
go back to reference Singh G, Athreya BH, Fries JF, Goldsmith DP: Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994, 37:1761–1769.CrossRefPubMed Singh G, Athreya BH, Fries JF, Goldsmith DP: Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994, 37:1761–1769.CrossRefPubMed
7.
go back to reference Feldman BM, Ayling-Campos A, Luy L, et al.: Measuring disability in juvenile dermatomyositis: validity of the Childhood Health Assessment Questionnaire. J Rheumatol 1995, 22:326–331.PubMed Feldman BM, Ayling-Campos A, Luy L, et al.: Measuring disability in juvenile dermatomyositis: validity of the Childhood Health Assessment Questionnaire. J Rheumatol 1995, 22:326–331.PubMed
8.
go back to reference Huber AM, Hicks JE, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic inflammatory myopathies. J Rheumatol 2001, 28:1106–1111.PubMed Huber AM, Hicks JE, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic inflammatory myopathies. J Rheumatol 2001, 28:1106–1111.PubMed
9.
go back to reference Lovell DJ, Lindsley CB, Rennebohm RM, et al.: Development of disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999, 42:2213–2219.CrossRefPubMed Lovell DJ, Lindsley CB, Rennebohm RM, et al.: Development of disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999, 42:2213–2219.CrossRefPubMed
10.
go back to reference Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale (CMAS) for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004, 50:1595–1603.CrossRefPubMed Huber AM, Feldman BM, Rennebohm RM, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale (CMAS) for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004, 50:1595–1603.CrossRefPubMed
11.
go back to reference Rennebohm RM, Jones K, Huber AM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale (CMAS). Arthritis Rheum 2004, 51:365–370.CrossRefPubMed Rennebohm RM, Jones K, Huber AM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale (CMAS). Arthritis Rheum 2004, 51:365–370.CrossRefPubMed
12.
go back to reference Ruperto N, Ravelli A, Murray KJ, et al.; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003, 42:1452–1459.CrossRefPubMed Ruperto N, Ravelli A, Murray KJ, et al.; Pediatric Rheumatology International Trials Organization (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology 2003, 42:1452–1459.CrossRefPubMed
13.
go back to reference Miller FW, Rider LG, Chung YL, et al.; International Myositis Outcome Assessment Collaborative Study Group: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2001, 40:1262–1273.CrossRef Miller FW, Rider LG, Chung YL, et al.; International Myositis Outcome Assessment Collaborative Study Group: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2001, 40:1262–1273.CrossRef
14.
go back to reference Hundley JL, Carroll CL, Lang W, et al.: Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol 2006, 54:217–220.CrossRefPubMed Hundley JL, Carroll CL, Lang W, et al.: Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol 2006, 54:217–220.CrossRefPubMed
15.
go back to reference Bode RK, Klein-Gitelman MS, Miller ML, et al.: Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Care Res 2003, 49:7–15.CrossRef Bode RK, Klein-Gitelman MS, Miller ML, et al.: Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Care Res 2003, 49:7–15.CrossRef
16.
go back to reference •• Ruperto N, Ravelli A, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): The provisional Pediatric Rheumatology International Trials Organization/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008, 59:4–13. This study provides valuable validation of several measures used in the assessment of children with myositis, based on the PRINTO core set measures.CrossRefPubMed •• Ruperto N, Ravelli A, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG): The provisional Pediatric Rheumatology International Trials Organization/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008, 59:4–13. This study provides valuable validation of several measures used in the assessment of children with myositis, based on the PRINTO core set measures.CrossRefPubMed
17.
go back to reference Isenberg D, Allen E, Farewell V, et al.; International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43:49–54.CrossRef Isenberg D, Allen E, Farewell V, et al.; International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43:49–54.CrossRef
18.
go back to reference Huber AM, Dugan EM, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: The Cutaneous Assessment Tool (CAT): development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007, 46:1606–1611.CrossRef Huber AM, Dugan EM, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: The Cutaneous Assessment Tool (CAT): development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford) 2007, 46:1606–1611.CrossRef
19.
go back to reference • Huber AM, Dugan EM, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Preliminary validation and clinical meaning of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis. Arthritis Rheum 2008, 59:214–221. This article provides validation for the only comprehensive skin assessment tool that is currently available.CrossRefPubMed • Huber AM, Dugan EM, Lachenbruch PA, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Preliminary validation and clinical meaning of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis. Arthritis Rheum 2008, 59:214–221. This article provides validation for the only comprehensive skin assessment tool that is currently available.CrossRefPubMed
20.
go back to reference Huber AM, Lachenbruch PA, Dugan EM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Alternative scoring of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis: results using an abbreviated format. Arthritis Rheum 2008, 59:352–356.CrossRefPubMed Huber AM, Lachenbruch PA, Dugan EM, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Alternative scoring of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis: results using an abbreviated format. Arthritis Rheum 2008, 59:352–356.CrossRefPubMed
21.
go back to reference Carroll CL, Lang W, Snively B, et al.: Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008, 158:345–350.PubMed Carroll CL, Lang W, Snively B, et al.: Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol 2008, 158:345–350.PubMed
22.
go back to reference Klein RQ, Bangert CA, Costner M, et al.: Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008, 159:887–894.CrossRefPubMed Klein RQ, Bangert CA, Costner M, et al.: Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol 2008, 159:887–894.CrossRefPubMed
23.
go back to reference Yassaee M, Fiorentino D, Okawa J, et al.: Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. Br J Dermatol 2009 Oct 26 (Epub ahead of print). Yassaee M, Fiorentino D, Okawa J, et al.: Modification of the Cutaneous Dermatomyositis Disease Area and Severity Index, an outcome instrument. Br J Dermatol 2009 Oct 26 (Epub ahead of print).
24.
go back to reference Rider LG, Feldman BM, Perez MD, et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent and patient global assessments. Arthritis Rheum 1997, 40:1976–1983.CrossRefPubMed Rider LG, Feldman BM, Perez MD, et al.: Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent and patient global assessments. Arthritis Rheum 1997, 40:1976–1983.CrossRefPubMed
25.
go back to reference • Rider LG, Lachenbruch PA, Monroe JB, et al.; IMACS Group: Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009, 60:3425–3435. This work validates the first (and currently only) damage assessment for children with myositis. It also documents and compares the extent of damage seen in both pediatric and adult myositis populations.CrossRefPubMed • Rider LG, Lachenbruch PA, Monroe JB, et al.; IMACS Group: Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009, 60:3425–3435. This work validates the first (and currently only) damage assessment for children with myositis. It also documents and compares the extent of damage seen in both pediatric and adult myositis populations.CrossRefPubMed
26.
go back to reference Landgraf J, Abetz L, Ware J: The CHQ User’s Manual. Boston, MA: The Health Institute; 1996. Landgraf J, Abetz L, Ware J: The CHQ User’s Manual. Boston, MA: The Health Institute; 1996.
27.
go back to reference • Apaz MT, Saad-Magalhães C, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation: Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009, 61:509–517. This is the only project to date to specifically study and validate a measure of health-related quality of life in a cohort of children with myositis.CrossRefPubMed • Apaz MT, Saad-Magalhães C, Pistorio A, et al.; Paediatric Rheumatology International Trials Organisation: Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum 2009, 61:509–517. This is the only project to date to specifically study and validate a measure of health-related quality of life in a cohort of children with myositis.CrossRefPubMed
28.
go back to reference Oddis CV, Rider LG, Reed AM, et al.; International Myositis Assessment and Clinical Studies Group: International consensus guidelines for the trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005, 52:2607–2615.CrossRefPubMed Oddis CV, Rider LG, Reed AM, et al.; International Myositis Assessment and Clinical Studies Group: International consensus guidelines for the trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005, 52:2607–2615.CrossRefPubMed
29.
go back to reference Rider LG, Giannini EH, Brunner HI, et al.; International Myositis Assessment and Clinical Studies Group: International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004, 50:2281–2290.CrossRefPubMed Rider LG, Giannini EH, Brunner HI, et al.; International Myositis Assessment and Clinical Studies Group: International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004, 50:2281–2290.CrossRefPubMed
30.
go back to reference Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344–347.PubMedCrossRef Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344–347.PubMedCrossRef
31.
go back to reference Rider LG, Schiffenbauer AS, Zito M, et al.; Juvenile Dermatomyositis Disease Activity Collaboration Study Group: Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 2002, 48:1681–1688.PubMed Rider LG, Schiffenbauer AS, Zito M, et al.; Juvenile Dermatomyositis Disease Activity Collaboration Study Group: Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 2002, 48:1681–1688.PubMed
32.
go back to reference O’Connor KA, Abbott KA, Sabin B, et al.: MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006, 120:319–325.CrossRefPubMed O’Connor KA, Abbott KA, Sabin B, et al.: MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. Clin Immunol 2006, 120:319–325.CrossRefPubMed
33.
go back to reference Bakay M, Wang Z, Melcon G, et al.: Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain 2006, 129:996–1013.CrossRefPubMed Bakay M, Wang Z, Melcon G, et al.: Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain 2006, 129:996–1013.CrossRefPubMed
34.
go back to reference Tezak Z, Hoffman EP, Lutz JL, et al.: Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002, 168:4154–4163.PubMed Tezak Z, Hoffman EP, Lutz JL, et al.: Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002, 168:4154–4163.PubMed
35.
go back to reference Fall N, Bove KE, Stringer K, et al.: Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis. Arthritis Rheum 2005, 52:3175–3180.CrossRefPubMed Fall N, Bove KE, Stringer K, et al.: Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis. Arthritis Rheum 2005, 52:3175–3180.CrossRefPubMed
36.
go back to reference Baechler EC, Bauer JW, Slattery CA, et al.: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13:59–68.CrossRefPubMed Baechler EC, Bauer JW, Slattery CA, et al.: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13:59–68.CrossRefPubMed
37.
go back to reference •• Feldman BM, Rider LG, Reed AM, Pachman LM: Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371:2201–2212. This is an outstanding review of the current state of knowledge about the pathogenesis of juvenile myositis, written by four leaders in the field.CrossRefPubMed •• Feldman BM, Rider LG, Reed AM, Pachman LM: Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008, 371:2201–2212. This is an outstanding review of the current state of knowledge about the pathogenesis of juvenile myositis, written by four leaders in the field.CrossRefPubMed
38.
go back to reference • Bilgic H, Ytterberg SR, Amin S, et al.: Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009, 60:3436–3446. This study documents the association between type I interferon-regulated genes and chemokines with disease activity and provides significant optimism that laboratory-based assessments of disease activity may be approaching development.CrossRefPubMed • Bilgic H, Ytterberg SR, Amin S, et al.: Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009, 60:3436–3446. This study documents the association between type I interferon-regulated genes and chemokines with disease activity and provides significant optimism that laboratory-based assessments of disease activity may be approaching development.CrossRefPubMed
39.
go back to reference Chung YL, Rider LG, Bell JD, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2005, 53:565–570.CrossRefPubMed Chung YL, Rider LG, Bell JD, et al.; Juvenile Dermatomyositis Disease Activity Collaborative Study Group: Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2005, 53:565–570.CrossRefPubMed
40.
go back to reference Eisenstein DM, O’Gorman MR, Pachman LM: Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J Rheumatol 1997, 24:1830–1832.PubMed Eisenstein DM, O’Gorman MR, Pachman LM: Correlations between change in disease activity and changes in peripheral blood lymphocyte subsets in patients with juvenile dermatomyositis. J Rheumatol 1997, 24:1830–1832.PubMed
41.
go back to reference O’Gorman MR, Bianchi L, Zaas D, et al.: Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis. Clin Diagn Lab Immunol 2000, 7:693–697.PubMed O’Gorman MR, Bianchi L, Zaas D, et al.: Decreased levels of CD54 (ICAM-1)-positive lymphocytes in the peripheral blood in untreated patients with active juvenile dermatomyositis. Clin Diagn Lab Immunol 2000, 7:693–697.PubMed
42.
go back to reference McCann LJ, Juggins AD, Maillard SM, et al.; Juvenile Dermatomyositis Research Group: The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006, 45:1255–1260.CrossRef McCann LJ, Juggins AD, Maillard SM, et al.; Juvenile Dermatomyositis Research Group: The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)—clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006, 45:1255–1260.CrossRef
43.
go back to reference Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for Juvenile Dermatomyositis, Paediatric Rheumatology European Society (PReS): An international consensus survey on the diagnostic criteria for juvenile dermatomyositis. Rheumatology (Oxford) 2006, 45:990–993.CrossRef Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for Juvenile Dermatomyositis, Paediatric Rheumatology European Society (PReS): An international consensus survey on the diagnostic criteria for juvenile dermatomyositis. Rheumatology (Oxford) 2006, 45:990–993.CrossRef
44.
go back to reference • Wedderburn LR, Varsani H, Li CK, et al.: International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007, 57:1192–1201. This work describes an attempt to standardize and validate the assessment of muscle biopsy specimens in juvenile myositis.CrossRefPubMed • Wedderburn LR, Varsani H, Li CK, et al.: International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007, 57:1192–1201. This work describes an attempt to standardize and validate the assessment of muscle biopsy specimens in juvenile myositis.CrossRefPubMed
45.
go back to reference Miles L, Bove KE, Lovell D, et al.: Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 2007, 57:1183–1191.CrossRefPubMed Miles L, Bove KE, Lovell D, et al.: Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients. Arthritis Rheum 2007, 57:1183–1191.CrossRefPubMed
46.
go back to reference • Gardner Medwin JM, Irwin G, Johnson K: MRI in juvenile idiopathic arthritis and juvenile dermatomyositis. Ann N Y Acad Sci 2009, 1154:52–83. This is an excellent review of the use of MRI in the assessment of children with myositis.CrossRefPubMed • Gardner Medwin JM, Irwin G, Johnson K: MRI in juvenile idiopathic arthritis and juvenile dermatomyositis. Ann N Y Acad Sci 2009, 1154:52–83. This is an excellent review of the use of MRI in the assessment of children with myositis.CrossRefPubMed
47.
go back to reference Maillard SM, Jones R, Owens C, et al.: Quantitative assessment of MRI T2 relaxation time in thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004, 43:603–608.CrossRef Maillard SM, Jones R, Owens C, et al.: Quantitative assessment of MRI T2 relaxation time in thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford) 2004, 43:603–608.CrossRef
48.
go back to reference Tzaribachev N, Well C, Schedel J, Horger M: Whole-body MRI: a helpful diagnostic tool for juvenile dermatomyositis case report and review of the literature. Rheumatol Int 2009, 29:1511–1514.CrossRefPubMed Tzaribachev N, Well C, Schedel J, Horger M: Whole-body MRI: a helpful diagnostic tool for juvenile dermatomyositis case report and review of the literature. Rheumatol Int 2009, 29:1511–1514.CrossRefPubMed
49.
go back to reference Summers RM, Brune AM, Choyke PL, et al.: Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery imaging. Radiology 1998, 209:191–196.PubMed Summers RM, Brune AM, Choyke PL, et al.: Juvenile idiopathic inflammatory myopathy: exercise-induced changes in muscle at short inversion time inversion-recovery imaging. Radiology 1998, 209:191–196.PubMed
50.
go back to reference Punaro L, Stichweh D, Powell M, et al.: Aspiration: hidden risk for patients with juvenile dermatomyositis [abstract]. Clin Exp Rheumatol 2004, 22(Suppl):S104. Punaro L, Stichweh D, Powell M, et al.: Aspiration: hidden risk for patients with juvenile dermatomyositis [abstract]. Clin Exp Rheumatol 2004, 22(Suppl):S104.
51.
go back to reference McCann LJ, Garay SM, Ryan MM, et al.: Oropharyngeal dysphagia in juvenile dermatomyositis (JDM):an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 2007, 46:1363–1366.CrossRefPubMed McCann LJ, Garay SM, Ryan MM, et al.: Oropharyngeal dysphagia in juvenile dermatomyositis (JDM):an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. Rheumatology 2007, 46:1363–1366.CrossRefPubMed
Metadata
Title
Update on the Assessment of Children with Juvenile Idiopathic Inflammatory Myopathy
Author
Adam M. Huber
Publication date
01-06-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 3/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0103-4

Other articles of this Issue 3/2010

Current Rheumatology Reports 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine